Article
All News
Article
Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
EULAR | The European League Against Rheumatism
Tweet
Reunite with old friends and extend your professional network at the #EULAR2019 Networking Platform in Hall 6. We hope you are enjoying your evening! https://t.co/zcqx9wHSmU
Dr. Dinesh Khanna
Tweet
Dr. Dinesh Khanna
Tweet
impact on mRSS in abatacept group whereas placebo did change (purple lines). Time for personalized medicine!! #EULAR2019 https://t.co/XmYLq8ddIp
Dr. Dinesh Khanna
Tweet
Early SSC is very hetogeneous disease. Data from the ASSET trial @bmsnews @UMIntMed and Whitfield lab (funded by @NIAIDNews) shows 1. Skin gene expression can largely be divided into 3 large groups with 41% with Normal like expression!! 2. Patients RX with abatacept had striking
Loreto Carmona 🖖
Tweet
We don’t take medications either because we can’t or because we don’t want to. Robert Horne on #adherence #EULAR2019 https://t.co/YUdLCfGErV
Dr. John Cush
Tweet
This was a great presentation - 36K ANA test, 7875 repeat ANAs (11% rheums 82% non-rheums) ~10% each went from Pos to Neg (or Neg to Pos) but only 5 new Rheumatic Dx made - incredibly low yield and low PPV https://t.co/Ng8Fg4k158
Dr. John Cush
Tweet
Tildrakizumab, an IL-12/p19 inhibitor, studied in 391 very active #PsA pts. Rx compared PBO vs 4 different doses and TIL showed superior ACR 20/50/70 responses (79.5%/52.6%/29.1% vs 24%PBO) and 80% PASI75 at wk24. #EULAR2019 LB0002 https://t.co/QKg0yDS28B
Leonard Calabrese
Tweet
I am so sorry to be missing EULAR this yr but feeling better!!! Will be Skyping in to the satellite Friday discussing what really matters to patients!!! @CCalabreseDO @RheumNow #IL6 @arthdoc https://t.co/teXkmmeAuo
David Liew
Tweet
Turned up to #EULAR2019 and immediately ran into three other Australians (separately). We’re all over this joint! @dr_rachelblack @tuna0sashimi 🇦🇺🇦🇺 @RheumNow https://t.co/kM7IHKQykf
Dr. John Cush
Tweet
Dr Jon Kay on “drift” of reference product. Lessons from Herceptin biosimilar development #eular2019 SP0014 https://t.co/uqWgYESe6N
Dr. John Cush
Tweet
DESIR 708 early TNFi naive axSpA finds only 36% started a TNFi & 49% switched to a 2nd TNFi & 47% to 3rd TNFi #EULAR2019 OP0012 https://t.co/5TMPofwRas
Janet Pope
Tweet
What happens when MTX-IR pts who don't respond to Adalimumab or Upadacitinib in Select compare RCT switch to other treatment? More switched out of adalimumab. Either group on average did well maybe switch to Upa a bit better but post hoc analysis. OP0029 #EULAR2019 @RheumNow https://t.co/sIG0kPPfNB
Alberta Hoi
Tweet
Ustekinumab in SLE, SLEDAI >=6 bilag 1A or 2B, ph2 results SRI-4 at w24 published. Sustained responses acc to SRI4, PGA, joint and CLASI to w48. Clasi even had higher response at w48. Those which switched to open label showed incremental improvement. Nice. #eular2019 @RheumNow
David Liew
Tweet
In a disease where there aren’t a lot of options, nintedanib reduces FVC rate of decline in SSc-ILD by >40%, independently of SSc subtype, antibody status, MMF exposure, just like it does in IPF.
Breathtaking results (so to speak) #EULAR2019 Distler for SENSCIS OP0017 @RheumNow https://t.co/eRsMxc7sdr https://t.co/LyqQf5apfx
Janet Pope
Tweet
New molecular pathway in RA. #EULAR2019 @RheumNow https://t.co/woTApyicbl
Janet Pope
Tweet
Tofacitinib results in Corrona over 5 yrs vs bDMARDs. Not randomized but propensity scores showed no increased serious infection, CV events and VTE found in Tofa vs bDMARDs. Slightly more HZ. Good and reassuring safety. OP0028 #EULAR2019 @RheumNow https://t.co/8ooYWmWvfV
Alberta Hoi
Tweet
Hendrika Bootsma presents her ASAP III study- monocentre double blinded randomised controlled study of abatacept vs placebo also negative other than esspri response difference at w12 and w24. Extension phase study to w48 with US and histology results #eular2019 @RheumNow
Sebastian C Rodriguez-García
Tweet
No point on repeating ANA testing PPV 0.01 according to this abstract by Yeo et al. #EULAR2019 #Rheumatology @RheumNow https://t.co/kX0angBvqd
